24/7 Market News Snapshot 03 October, 2025 – IceCure Medical Ltd. Ordinary Shares (NASDAQ:ICCM)

October 3, 2025

DENVER, Colo., 03 October, 2025 (www.247marketnews.com) – (NASDAQ:ICCM) are discussed in this article.
IceCure Medical Ltd. has experienced a notable surge in its stock price, opening at $0.99 and currently trading at $1.118, which marks an impressive increase of 12.93% from the previous closing price. The substantial trading volume of 5.36 million shares indicates heightened investor interest and robust market activity surrounding the company. This upward trend could be attributed to favorable developments anticipated from the company’s product offerings, highlighting a positive sentiment among stakeholders. As the trading session progresses, investors are encouraged to monitor technical indicators that suggest a bullish trend, paying close attention to potential resistance and support levels that may influence future price movements.

A pivotal factor contributing to this investor sentiment is the recent announcement regarding the FDA marketing authorization of IceCure’s ProSense® cryoablation system. This groundbreaking therapy represents a significant advancement in treatment for early-stage, low-risk breast cancer, being the first medical device of its kind to gain FDA approval specifically for this indication. The ProSense® system offers patients aged 70 and above a minimally invasive alternative to conventional surgical methods. Utilizing state-of-the-art cryoablation technology, the system destroys tumors through freezing, which preserves adjacent healthy tissues and minimizes cosmetic changes.

The outpatient procedure is designed for efficiency, usually taking between 30 to 45 minutes, with patients often returning to their daily routines within 24 hours post-treatment. CEO Eyal Shamir emphasized the company’s commitment to empowering women diagnosed with low-risk early-stage breast cancer by providing a safe and effective treatment option that prioritizes both health outcomes and quality of life.

The FDA’s authorization follows comprehensive data from the ICE3 trial, which is recognized as the largest clinical study related to liquid-nitrogen-based cryoablation. This trial demonstrated a low five-year recurrence rate of 3.1% for patients treated with ProSense® alongside endocrine therapy, which is comparable to traditional lumpectomy results. Moving forward, IceCure plans to validate the system’s efficacy further through post-market surveillance studies involving approximately 400 patients across multiple sites, thereby reinforcing its commitment to innovate and enhance breast cancer treatment options.

Related news for (ICCM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.